医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ascend Performance Materials Announces Price Increase for Intermediate Materials

2020年09月11日 AM01:01
このエントリーをはてなブックマークに追加


 

HOUSTON

Ascend Performance Materials announced today a price increase for intermediate materials.

The price increase takes effect immediately and includes the following terms:

Material

Price Increase

Terms

Hexamethylene Diamine (HMD)

$100/MT

  • As contracts allow
  • Non-contract business – price determined on an order-by-order basis

Adiponitrile (ADN)

$100/MT

  • As contracts allow
  • Non-contract business – price determined on an order-by-order basis

Acrylonitrile (AN)

$85/MT

  • As contracts allow
  • Non-contract business – price determined on an order-by-order basis

Adipic Acid (AA)

$80/MT

  • As contracts allow
  • Non-contract business – price determined on an order-by-order basis

Customers should contact their local sales representative for additional information.

About Ascend Performance Materials

Ascend Performance Materials makes high-performance materials for everyday essentials and new technologies. Our focus is on improving quality of life and inspiring a better tomorrow through innovation. Based in Houston, Texas, and with regional offices in Shanghai, Brussels and Detroit, we are a fully integrated material solutions provider with eight global manufacturing facilities in the United States, Europe and China. Our 2,600-person global workforce makes the plastics, fabrics, fibers and chemicals used to make safer vehicles, cleaner energy, better medical devices, smarter appliances and longer-lasting apparel and consumer goods. We are committed to safety, sustainability and the success of our customers and our communities.

Find out more about Ascend at www.ascendmaterials.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005789/en/

CONTACT

Alison Jahn at +1 713-210-9809, ajahn@ascendmaterials.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates